Availability and prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022

Availability

We analyzed data from National Survey of Substance Abuse Treatment Services (N-SSATS) from 2017-2020(12) and the National Substance Use and Mental Health Services Survey (N-SUMHSS) from 2021.(13) These surveys, conducted by the SAMHSA, collect data on public and private substance abuse treatment facilities in the US. We restricted analysis to facilities that reported offering medications approved for OUD treatment including extended-release naltrexone, methadone, oral buprenorphine (with or with naloxone), INJ-BUP, and the buprenorphine implant (discontinued in 2020). We report the number and percentage of facilities that reported offering each route of buprenorphine and accepting Medicaid insurance, overall and by state. We also calculated the number of facilities per 1000 Medicaid beneficiaries treated for an OUD. For the number of beneficiaries treated for an OUD, we took the average of the numbers reported in the 2019 and 2020 Interactive T-MSIS SUD Date Book (from Table G.2 in the reference).(14)

Prescribing

We analyzed State Drug Utilization Data (SDUD) from 2017-2022.(15) SDUD are reported by states for outpatient medications paid for by state Medicaid agencies. SDUD include the count of prescription fills for each National Drug Code (NDC) by calendar quarter, overall and by state. We identified buprenorphine prescriptions including route using a list of NDCs compiled from the Centers for Disease Control and Prevention’s Opioid NDC and Oral MME Conversion File 2017-2020 and the Centers for Medicare and Medicaid Services Chronic Conditions Data Warehouse definition for OUD. In SDUD, counts <11 are suppressed; we imputed suppressed counts with 5.5. We report the total count of prescription fills for each route of buprenorphine, overall and by state. We also calculated the number of prescriptions per 1000 Medicaid beneficiaries treated for an OUD (denominator described above).

Availability

The total number of substance abuse treatment facilities included in the N-SSATS and N-SUMHSS surveys that reported offering any medication for OUD treatment increased from 14,667 in 2018 (the first full year INJ-BUP was approved) to 17,333 in 2021 (Table 1). INJ-BUP was available at 360 facilities that accept Medicaid (2.5% of all SUD facilities offering medication) in 2018. That number increased steadily over the first four years 2,257 (13% of facilities) in 2021. In contrast, the percentage of facilities offering oral buprenorphine and accepting Medicaid increased from 23% to 36%. In 2021, for every 1000 Medicaid beneficiaries with OUD, there were approximately 3.9 facilities offering oral buprenorphine and 1.4 facilities offering INJ-BUP.

Figure 1A depicts the number of facilities in each state by year (numbers provided in Appendix Table 1). In 2018, there were 5 states that did not have a single facility offering INJ-BUP and accepting Medicaid and most states (n=30) had <5 facilities. By 2019, there was just a single state (South Dakota) without any facilities and 7 states with <5. By 2020, all states had at least one facility. The median number of facilities offering INJ-BUP and accepting Medicaid in each state increased from 4 (interquartile range [IQR] 2-9) in 2018 to 29 (IQR 14-67) in 2021 (Table 2). Figure 1B depicts the percentage of facilities offering INJ-BUP and accepting Medicaid (of all SUD facilities offering medication) in each state by year (numbers provided in Appendix Table 2). The median percentage in each state increased from 1.9% (IQR 1.0-3.5) to 12.8 (IQR 8.5-18.9) (Table 2).

• Download figure
• Open in new tab

Figure 1.

Substance use disorder treatment facilities that offered buprenorphine injection and accepted Medicaid insurance: absolute number (A) and as a percentage of all facilities offering medication for opioid use disorder (B). In each panel states are sorted by statistic in 2021. Arrows indicate that value exceeds the x-axis upper limit and are shown in the inset table. * marks states without Medicaid coverage for buprenorphine injection in 2018.

Prescribing

Nationwide, there were 4,322 prescriptions for INJ-BUP paid by Medicaid in 2018, the first year it was available (Table 1). The number of prescriptions exponentially increased from 2018 to 2022. In 2022, there were 186,861 prescriptions. In contrast, the number of oral buprenorphine prescriptions increased from 6.4 million in 2018 to 9.1 million in 2022. In 2022, 2.0% of all buprenorphine prescriptions paid by Medicaid were INJ-BUP. In that year, there were approximately 1.2 prescriptions of INJ-BUP and 56.9 prescriptions of oral buprenorphine per 10 beneficiaries with OUD.

Figure 2A depicts the number of INJ-BUP prescriptions in each state by year (numbers provided in Appendix Table 1). In 2018, there were 13 states with more than 100 prescriptions for INJ-BUP. This number increased to 31 states in 2019, 36 states in 2020, and 40 states in 2021 and 2022. In 2022, 2 states did not report any prescriptions for INJ-BUP (Arkansas and Texas). The median number of prescriptions in each state went from 31 (IQR 11-107) in 2018 to 1786 (IQR 325-3609) in 2022 (Table 2). Figure 2B depicts the proportion of all buprenorphine prescriptions that were for INJ-BUP in each state by year (numbers provided in Appendix Table 2). The median percentage of prescriptions that were for INJ-BUP in each state increased from 0.1% (IQR 0.0%-0.1%) to 1.1% (IQR 0.8%-2.6%) (Table 2).

• Download figure
• Open in new tab

Figure 2.

Prescription for buprenorphine injection paid by Medicaid: absolute number (A) and as a percentage of all buprenorphine prescriptions for opioid use disorder. In each panel states are sorted by statistic in 2022. Arrows indicate that value exceeds the x-axis upper limit and are shown in the inset table. * marks states without Medicaid coverage for buprenorphine injection in 2018.